• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用追回的脱落数据对事件时间终点缺失数据进行插补。

Imputation of Missing Data for Time-to-Event Endpoints Using Retrieved Dropouts.

机构信息

Pfizer Inc., 1 Portland St, Cambridge, MA, 02139, USA.

Pfizer Inc., 66 Hudson Blvd, New York, NY, 10001, USA.

出版信息

Ther Innov Regul Sci. 2024 Jan;58(1):114-126. doi: 10.1007/s43441-023-00575-5. Epub 2023 Oct 7.

DOI:10.1007/s43441-023-00575-5
PMID:37805643
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10764582/
Abstract

We have explored several statistical approaches to impute missing time-to-event data that arise from outcome trials with relatively long follow-up periods. Aligning with the primary estimand, such analyses evaluate the robustness of results by imposing an assumption different from censoring at random (CAR). Although there have been debates over which assumption and which method is more appropriate to be applied to the imputation, we propose to use the collection of retrieved dropouts as the basis of missing data imputation. As retrieved dropouts share a similar disposition, such as treatment discontinuation, with subjects who have missing data, they can reasonably be assumed to characterize the distribution of time-to-event among subjects with missing data. In terms of computational intensity and robustness to violation of underlying distributional assumption, we have compared parametric approaches via MCMC or MLE multivariate sampling procedures to a non-parametric bootstrap approach with respect to baseline hazard function. Each of these approaches follows a process of multiple imputation ("proper imputations"), analysis of complete datasets, and final combination. The type-I error, and power rates are examined under a wide range of scenarios to inform the performance characteristics. A subset of a real unblinded phase III CVOT is used to demonstrate the application of the proposed approaches, compared to the Cox proportional hazards model and jump-to-reference multiple imputation.

摘要

我们已经探索了几种统计方法来估算来自具有相对较长随访期的结局试验的缺失生存时间数据。这些分析与主要的估计量一致,通过施加不同于随机删失(CAR)的假设来评估结果的稳健性。虽然对于哪种假设和哪种方法更适合应用于插补存在争议,但我们建议使用检索到的失访者集合作为缺失数据插补的基础。由于检索到的失访者与缺失数据的受试者具有相似的处置,例如治疗中断,因此可以合理地假设它们可以描述缺失数据受试者的生存时间分布。在计算强度和对基础分布假设违反的稳健性方面,我们比较了参数方法,通过 MCMC 或 MLE 多元抽样程序,与基于基线风险函数的非参数引导方法。这些方法中的每一种都遵循多次插补(“适当插补”)、完整数据集分析和最终组合的过程。在广泛的场景下检查了Ⅰ型错误和功效率,以告知性能特征。使用真实的非盲 III 期 CVOT 的一个子集来演示所提出的方法的应用,与 Cox 比例风险模型和跳跃参考多重插补进行比较。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e86/10764582/b9e234a22fb1/43441_2023_575_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e86/10764582/d0a10503dfcf/43441_2023_575_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e86/10764582/b9e234a22fb1/43441_2023_575_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e86/10764582/d0a10503dfcf/43441_2023_575_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e86/10764582/b9e234a22fb1/43441_2023_575_Fig2_HTML.jpg

相似文献

1
Imputation of Missing Data for Time-to-Event Endpoints Using Retrieved Dropouts.利用追回的脱落数据对事件时间终点缺失数据进行插补。
Ther Innov Regul Sci. 2024 Jan;58(1):114-126. doi: 10.1007/s43441-023-00575-5. Epub 2023 Oct 7.
2
Impute the missing data using retrieved dropouts.使用检索到的辍学数据来推断缺失的数据。
BMC Med Res Methodol. 2022 Mar 27;22(1):82. doi: 10.1186/s12874-022-01509-9.
3
Strengthening the interpretability of clinical trial results by assessing the effect of informative censoring on the primary estimand in PRECISION.通过评估信息性删失对 PRECISION 中主要估计量的影响来增强临床试验结果的可解释性。
Clin Trials. 2020 Oct;17(5):535-544. doi: 10.1177/1740774520934747. Epub 2020 Jul 9.
4
A wide range of missing imputation approaches in longitudinal data: a simulation study and real data analysis.多种缺失值插补方法在纵向数据分析中的应用:一项模拟研究与真实数据分析。
BMC Med Res Methodol. 2023 Jul 6;23(1):161. doi: 10.1186/s12874-023-01968-8.
5
Control-based imputation for sensitivity analyses in informative censoring for recurrent event data.用于复发事件数据信息删失中敏感性分析的基于对照的插补法。
Pharm Stat. 2017 Nov;16(6):424-432. doi: 10.1002/pst.1821. Epub 2017 Aug 22.
6
Estimation of a treatment policy estimand for time to event data using data collected post discontinuation of randomised treatment.利用随机治疗停止后收集的数据对事件发生时间数据的治疗策略估计量进行估计。
Pharm Stat. 2022 May;21(3):612-624. doi: 10.1002/pst.2189. Epub 2022 Jan 7.
7
A hybrid return to baseline imputation method to incorporate MAR and MNAR dropout missingness.一种混合的回归到基线填补方法,用于纳入 MAR 和 MNAR 缺失。
Contemp Clin Trials. 2022 Sep;120:106859. doi: 10.1016/j.cct.2022.106859. Epub 2022 Jul 21.
8
Imputation strategies when a continuous outcome is to be dichotomized for responder analysis: a simulation study.当连续结果需要二分类化进行应答者分析时的推断策略:一项模拟研究。
BMC Med Res Methodol. 2019 Jul 23;19(1):161. doi: 10.1186/s12874-019-0793-x.
9
Retrieved-Dropout-Based multiple imputation for time-to-event data in cardiovascular outcome trials.心血管结局试验中基于检索式失访的生存数据多重填补法
J Biopharm Stat. 2023 Mar;33(2):234-252. doi: 10.1080/10543406.2022.2118763. Epub 2022 Sep 19.
10
Reference-based sensitivity analysis for time-to-event data.基于参考的生存时间数据敏感性分析。
Pharm Stat. 2019 Nov;18(6):645-658. doi: 10.1002/pst.1954. Epub 2019 Jul 15.

引用本文的文献

1
Comprehensive implementations of multiple imputation using retrieved dropouts for continuous endpoints.使用检索到的失访数据对连续终点进行多重填补的综合实施方法。
BMC Med Res Methodol. 2025 Feb 21;25(1):47. doi: 10.1186/s12874-025-02494-5.

本文引用的文献

1
Retrieved-Dropout-Based multiple imputation for time-to-event data in cardiovascular outcome trials.心血管结局试验中基于检索式失访的生存数据多重填补法
J Biopharm Stat. 2023 Mar;33(2):234-252. doi: 10.1080/10543406.2022.2118763. Epub 2022 Sep 19.
2
Impute the missing data using retrieved dropouts.使用检索到的辍学数据来推断缺失的数据。
BMC Med Res Methodol. 2022 Mar 27;22(1):82. doi: 10.1186/s12874-022-01509-9.
3
Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects.
癌症患者的生存情况可以参数化,以提高试验精度并揭示时间依赖性治疗效果。
Nat Commun. 2022 Feb 15;13(1):873. doi: 10.1038/s41467-022-28410-9.
4
Return-to-baseline multiple imputation for missing values in clinical trials.临床试验中缺失值的基线回归多重插补。
Pharm Stat. 2022 May;21(3):641-653. doi: 10.1002/pst.2191. Epub 2022 Jan 5.
5
Quantifying Withdrawal of Consent, Loss to Follow-Up, Early Drug Discontinuation, and Censoring in Oncology Trials.量化肿瘤学试验中同意撤回、失访、早期药物停用及删失情况
J Natl Compr Canc Netw. 2021 Sep 3;19(12):1433-1440. doi: 10.6004/jnccn.2021.7015.
6
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.在 2 型糖尿病中使用 Efpeglenatide 的心血管和肾脏结局。
N Engl J Med. 2021 Sep 2;385(10):896-907. doi: 10.1056/NEJMoa2108269. Epub 2021 Jun 28.
7
Dapagliflozin in Patients with Chronic Kidney Disease.达格列净治疗慢性肾脏病患者。
N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24.
8
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.在 2 型糖尿病患者中使用依格列净的心血管结局。
N Engl J Med. 2020 Oct 8;383(15):1425-1435. doi: 10.1056/NEJMoa2004967. Epub 2020 Sep 23.
9
Informative censoring - a neglected cause of bias in oncology trials.信息删失——肿瘤学试验中一个被忽视的偏倚原因。
Nat Rev Clin Oncol. 2020 Jun;17(6):327-328. doi: 10.1038/s41571-020-0368-0.
10
Impact of informative censoring on the treatment effect estimate of disability worsening in multiple sclerosis clinical trials.信息性删失对多发性硬化症临床试验中残疾恶化治疗效果估计的影响。
Mult Scler Relat Disord. 2020 Apr;39:101865. doi: 10.1016/j.msard.2019.101865. Epub 2019 Nov 23.